Slide decks and videos
Click on any video or slide deck title to view or download that resource.
Recent developments for first-line bevacizumab in lung cancer
Professor Jean-Charles Soria reviews efficacy and safety data for Avastin plus chemotherapy across clinical trials in NSCLC at the Roche Anti-angiogenesis Investigator Meeting during ASCO 2010 in Chicago, USA in June 2010.
The SAiL experience
SAiL investigator Professor Lucio Crino discusses the clinical relevance of newly reported data for Avastin in NSCLC.
The molecular basis of cancer
Professor Roman Pérez-Soler summarises the current state of knowledge and evolving concepts regarding malignant transformation and cancer pathogenesis.
Precise VEGF targeting for sustained clinical benefit in first-line NSCLC
Dr Anne Tsao highlights the efficacy of first-line Avastin in combination with chemotherapy in non-squamous NSCLC at the Horizons IV Lung Cancer Expert Forum in Berlin, Germany in September 2009.
Controlling angiogenesis to control tumour growth
Professor Fairooz Kabbinavar discusses angiogenesis – a fundamental process for tumour growth – and how Avastin targets VEGF, the key driver of angiogenesis, at the Anti-angiogenesis Clinical Experience Exchange Meeting in Madrid, Spain in April 2009.
Bevacizumab plus IFN: delivering clinical benefit in mRCC
Professor Camillo Porta presents the latest clinical trial data on the efficacy of first-line Avastin plus IFN in mRCC at the F. Hoffmann-La Roche satellite symposium at ECCO/ESMO 2009 in Berlin, Germany in September 2009.
Moving beyond convention: anti-angiogenic therapy in cancer (NSCLC)
Professor Frank Griesinger presents the latest clinical trial data on the efficacy of first-line Avastin-based therapy in advanced NSCLC at the F. Hoffmann-La Roche satellite symposium at ECCO/ESMO 2009 in Berlin, Germany in September 2009.
Understanding the mode of action of Avastin
This slide deck summarises the data on the anti-angiogenic effects of Avastin, including regression of tumour vasculature, normalisation of surviving vasculature and inhibition of new and recurrent tumour vessel growth.
Bevacizumab safety in patients with CNS metastases
This slide deck presents findings from a retrospective analysis of more than 12,000 patients across several tumour types, which demonstrated that the risk of cerebral haemorrhage, in the presence of CNS metastases, is independent of Avastin therapy.
The quest for angiogenesis biomarkers
This presentation highlights some of the known prognostic and predictive angiogenesis biomarkers used in oncology. Through clinical trials of Avastin, a number of potential biomarkers have been identified.
- Disclaimer: Avastin.net is a comprehensive resource for healthcare professionals outside the US. If you are a US resident please visit www.avastin.comThe information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.